PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+18.47%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.84B
AUM Growth
+$2.84B
(+33%)
Cap. Flow
+$546M
Cap. Flow
% of AUM
19.24%
Top 10 Holdings %
Top 10 Hldgs %
58.91%
Holding
39
New
10
Increased
16
Reduced
5
Closed
5
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$140M |
| 2 |
Revolution Medicines
RVMD
|
$93.9M |
| 3 |
Vaxcyte
PCVX
|
$84.7M |
| 4 |
Arvinas
ARVN
|
$69.5M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
$66.8M |
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cullinan Oncology
CGEM
$445M
| $23M | 0.81% | +1,348,015 | New | +$23M |
|
27
Apogee Therapeutics
APGE
$2.17B
| $21.9M | 0.77% | +330,000 | New | +$21.9M |
|
|
CMPS
28
Compass Pathways
CMPS
$424M
| $19.9M | 0.7% | 2,390,988 +125,000 | +6% | +$1.04M |
|
29
Vor Biopharma
VOR
$250M
| $15.3M | 0.54% | 6,457,293 | – | – |
|
30
Zentalis Pharmaceuticals
ZNTL
$122M
| $14.9M | 0.52% | 944,917 +544,917 | +136% | +$8.59M |
|
31
Agios Pharmaceuticals
AGIO
$2.19B
| $11.7M | 0.41% | +400,000 | New | +$11.7M |
|
32
Caribou Biosciences
CRBU
$174M
| $11.2M | 0.39% | 2,172,620 -751,231 | -26% | -$3.86M |
|
|
CRGX
33
DELISTED
CARGO Therapeutics
CRGX
| $3.3M | 0.12% | 147,959 -185,374 | -56% | -$4.14M |
|
34
Kyverna Therapeutics
KYTX
$160M
| $1.24M | 0.04% | +50,000 | New | +$1.24M |
|
|
JBIO
35
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| – | – | -143,235 | Closed | -$3.24M |
|
36
TG Therapeutics
TGTX
$4.65B
| – | – | -2,171,419 | Closed | -$37.1M |
|
37
Zai Lab
ZLAB
$3.68B
| – | – | -1,091,779 | Closed | -$29.8M |
|
|
AMAM
38
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| – | – | -4,352,689 | Closed | -$62M |
|
|
MRTX
39
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – | -1,543,116 | Closed | -$90.7M |
|